AR106914A1 - Factor viii con propiedades de unión a ligando reducidas y vida media extendida - Google Patents
Factor viii con propiedades de unión a ligando reducidas y vida media extendidaInfo
- Publication number
- AR106914A1 AR106914A1 ARP160103731A ARP160103731A AR106914A1 AR 106914 A1 AR106914 A1 AR 106914A1 AR P160103731 A ARP160103731 A AR P160103731A AR P160103731 A ARP160103731 A AR P160103731A AR 106914 A1 AR106914 A1 AR 106914A1
- Authority
- AR
- Argentina
- Prior art keywords
- fviii
- modified
- recombinant
- factor viii
- lrp1
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title abstract 17
- 108010054218 Factor VIII Proteins 0.000 abstract 16
- 102000001690 Factor VIII Human genes 0.000 abstract 16
- 108010047303 von Willebrand Factor Proteins 0.000 abstract 5
- 102100036537 von Willebrand factor Human genes 0.000 abstract 5
- 229960001134 von willebrand factor Drugs 0.000 abstract 5
- 238000012986 modification Methods 0.000 abstract 3
- 230000004048 modification Effects 0.000 abstract 3
- 102000000853 LDL receptors Human genes 0.000 abstract 2
- 108010001831 LDL receptors Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000007547 defect Effects 0.000 abstract 2
- 230000002008 hemorrhagic effect Effects 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicación 1: Un Factor VIII (FVIII) modificado, caracterizado porque comprende a modificación que aumenta la vida media del FVIII y reduce la unión de dicho FVIII modificado a un ligando seleccionado del grupo que consiste en el Factor de von Willebrand (VWF) y la proteína relacionada con el receptor de lipoproteínas de baja densidad (LDL) 1 (LRP1). Reivindicación 11: Una composición farmacéutica, caracterizada porque comprende el Factor VIII modificado de acuerdo con cualquiera de las reivindicaciones 1 - 10 y un vehículo, diluyente, sal, solución amortiguadora o excipiente farmacéuticamente aceptable. Reivindicación 16: Un FVIII recombinante, modificado, caracterizado porque comprende una modificación que aumenta la vida media del FVIII y reduce la unión de dicho FVIII modificado a un ligando seleccionado del grupo que consiste VWF y LRP1, en donde dicha modificación comprende un PSA con un conector de aminooxi, y en donde dicho conector de aminooxi está unido a un carbohidrato oxidado de dicho FVIII modificado; en donde la vida media de dicho FVIII recombinante, modificado que mas prolongada que un FVIII recombinante, no modificado y/o un FVIII recombinante, PEGilado; y en donde la unión al VWF o a la LRP1 de dicho FVIII recombinante, modificado es menor en comparación con la unión del VWF o de la LRP1 de un FVIII recombinante, no modificado y/o de un FVIII recombinante, PEGilado. Reivindicación 18: Un método de tratamiento de un defecto hemorrágico en un mamífero, caracterizado porque comprende el paso de administrar el Factor VIII modificado de cualquiera de las reivindicaciones 1 - 10 y 12 - 16, o la composición farmacéutica de la reivindicación 11, al mamífero en una cantidad eficaz para reducir o eliminar uno o más síntomas de dicho defecto hemorrágico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562262674P | 2015-12-03 | 2015-12-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106914A1 true AR106914A1 (es) | 2018-02-28 |
Family
ID=57614469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103731A AR106914A1 (es) | 2015-12-03 | 2016-12-05 | Factor viii con propiedades de unión a ligando reducidas y vida media extendida |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20170349644A1 (es) |
| EP (1) | EP3383895A1 (es) |
| JP (1) | JP2019510022A (es) |
| KR (1) | KR20180088727A (es) |
| CN (1) | CN108884146A (es) |
| AR (1) | AR106914A1 (es) |
| AU (1) | AU2016362606A1 (es) |
| BR (1) | BR112018011259A2 (es) |
| CA (1) | CA3007364A1 (es) |
| EA (1) | EA201891333A1 (es) |
| IL (1) | IL259760A (es) |
| MX (1) | MX2018006738A (es) |
| PH (1) | PH12018501174A1 (es) |
| SG (2) | SG11201804666QA (es) |
| TW (1) | TW201731869A (es) |
| WO (1) | WO2017096383A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| US20170349644A1 (en) * | 2015-12-03 | 2017-12-07 | Baxalta Incorporated | Factor viii with extended half-life and reduced ligand-binding properties |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| US5250421A (en) | 1986-01-03 | 1993-10-05 | Genetics Institute, Inc. | Method for producing factor VIII:C-type proteins |
| JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| KR100303872B1 (ko) | 1992-10-02 | 2001-11-22 | 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 | 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법 |
| WO1996040662A2 (en) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Aminooxy-containing linker compounds and their application in conjugates |
| CA2349468C (en) | 1998-11-10 | 2013-07-09 | Baxter Aktiengesellschaft | Factor viii polypeptide having factor viii:c activity |
| ATE313554T1 (de) | 2000-05-16 | 2006-01-15 | Lipoxen Technologies Ltd | Derivatisierung von proteinen in wässrigem lösungsmittel |
| US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| EP1681303B1 (en) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
| US20080206182A1 (en) | 2003-08-08 | 2008-08-28 | Fresenius Kabi Deutschland Gmbh | Conjugates of a Polymer and a Protein Linked by an Oxime Group |
| EP1654290B1 (en) | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| CN101870729A (zh) * | 2003-09-09 | 2010-10-27 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
| US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| KR101237884B1 (ko) | 2003-12-03 | 2013-02-27 | 바이오제너릭스 에이지 | 글리코 peg화 과립구 콜로니 자극인자 |
| ES2593318T3 (es) | 2004-08-12 | 2016-12-07 | Lipoxen Technologies Limited | Derivados de ácido siálico |
| EP1799249A2 (en) | 2004-09-10 | 2007-06-27 | Neose Technologies, Inc. | Glycopegylated interferon alpha |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| US20100056428A1 (en) | 2006-09-01 | 2010-03-04 | Novo Nordisk Health Care Ag | Modified proteins |
| EP2257311B1 (en) * | 2008-02-27 | 2014-04-16 | Novo Nordisk A/S | Conjugated factor viii molecules |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| RU2595442C2 (ru) * | 2009-07-27 | 2016-08-27 | Баксалта Инкорпорейтед | Конъюгаты белков свертывания крови |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| US9062299B2 (en) * | 2009-08-24 | 2015-06-23 | Amunix Operating Inc. | Coagulation factor IX compositions and methods of making and using same |
| EP3505186B1 (en) * | 2010-07-30 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Nucleophilic catalysts for oxime linkage |
| CN104519897A (zh) * | 2012-06-08 | 2015-04-15 | 比奥根艾迪克Ma公司 | 促凝血化合物 |
| US20170349644A1 (en) * | 2015-12-03 | 2017-12-07 | Baxalta Incorporated | Factor viii with extended half-life and reduced ligand-binding properties |
-
2016
- 2016-12-05 US US15/369,529 patent/US20170349644A1/en not_active Abandoned
- 2016-12-05 AU AU2016362606A patent/AU2016362606A1/en not_active Abandoned
- 2016-12-05 JP JP2018549130A patent/JP2019510022A/ja active Pending
- 2016-12-05 CA CA3007364A patent/CA3007364A1/en not_active Abandoned
- 2016-12-05 WO PCT/US2016/064979 patent/WO2017096383A1/en not_active Ceased
- 2016-12-05 CN CN201680078827.1A patent/CN108884146A/zh active Pending
- 2016-12-05 EP EP16819236.7A patent/EP3383895A1/en not_active Withdrawn
- 2016-12-05 KR KR1020187018942A patent/KR20180088727A/ko not_active Withdrawn
- 2016-12-05 MX MX2018006738A patent/MX2018006738A/es unknown
- 2016-12-05 EA EA201891333A patent/EA201891333A1/ru unknown
- 2016-12-05 AR ARP160103731A patent/AR106914A1/es unknown
- 2016-12-05 SG SG11201804666QA patent/SG11201804666QA/en unknown
- 2016-12-05 SG SG10202004031WA patent/SG10202004031WA/en unknown
- 2016-12-05 BR BR112018011259A patent/BR112018011259A2/pt not_active Application Discontinuation
- 2016-12-05 TW TW105140136A patent/TW201731869A/zh unknown
-
2018
- 2018-06-03 IL IL259760A patent/IL259760A/en unknown
- 2018-06-04 PH PH12018501174A patent/PH12018501174A1/en unknown
-
2019
- 2019-02-22 US US16/283,525 patent/US20190240295A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20190240295A1 (en) | 2019-08-08 |
| TW201731869A (zh) | 2017-09-16 |
| SG11201804666QA (en) | 2018-06-28 |
| BR112018011259A2 (pt) | 2018-11-21 |
| IL259760A (en) | 2018-07-31 |
| CA3007364A1 (en) | 2017-06-08 |
| KR20180088727A (ko) | 2018-08-06 |
| EP3383895A1 (en) | 2018-10-10 |
| MX2018006738A (es) | 2018-09-21 |
| EA201891333A1 (ru) | 2018-12-28 |
| AU2016362606A1 (en) | 2018-06-28 |
| JP2019510022A (ja) | 2019-04-11 |
| WO2017096383A1 (en) | 2017-06-08 |
| US20170349644A1 (en) | 2017-12-07 |
| SG10202004031WA (en) | 2020-05-28 |
| PH12018501174A1 (en) | 2019-01-21 |
| CN108884146A (zh) | 2018-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2533874T3 (es) | Armazón proteico | |
| CY1123385T1 (el) | Υψηλης συγγενειας pd-1 παραγοντες και μεθοδοι χρησης | |
| ES2540858T3 (es) | Composición farmacéutica para el tratamiento y/o la prevención de cáncer | |
| AR087091A1 (es) | Polipeptidos quimericos e hibridos del factor viii, y sus metodos de uso | |
| PE20181338A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones terapeuticas que los comprenden | |
| MX2016004579A (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| PE20130041A1 (es) | Proteinas de dominio de andamiaje de fibronectina que se unen a interleucina 23 (il-23) | |
| HRP20220960T1 (hr) | Kimerni proteini faktora viii i njihova upotreba | |
| MX2015000397A (es) | Complejo del factor viii con xten y proteina del factor von willebrand, y sus usos. | |
| BR112018073289A2 (pt) | moléculas de ligação, polinucleotídeo isolado, vetor, célula hospedeira, métodos para produzir a molécula de ligação, para tratar um indivíduo com câncer e para regular positivamente ou prolongar a atividade de células t, composição farmacêutica e uso da molécula de ligação | |
| RU2014103288A (ru) | Слитые полипептиды релаксина и их применение | |
| AR089324A1 (es) | Composiciones, metodos y kits para la preparacion de proteinas recombinantes sialiladas | |
| PE20141271A1 (es) | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 | |
| JP2015519313A5 (es) | ||
| MY192113A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| AR080027A1 (es) | Proteinas de union a cd127 | |
| EA201792245A1 (ru) | Биоконъюгаты и их применения | |
| PE20141473A1 (es) | Senalizacion slit-robo para el diagnostico y tratamiento de la enfermedad renal | |
| BR112019004459A2 (pt) | métodos para purificar anticorpos | |
| JP2025016467A (ja) | 改善された薬物動態を有する、グリコシル化ｖｗｆ融合タンパク質 | |
| AR106914A1 (es) | Factor viii con propiedades de unión a ligando reducidas y vida media extendida | |
| RU2018128582A (ru) | Мутированный укороченный фактор фон виллебранда | |
| JP2013519698A5 (es) | ||
| CL2019003405A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407) | |
| CL2020003293A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 42; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |